ALBERTA PRECISION LABORATORIES
Leaders in Laboratory Medicine

Laboratory Bulletin

DATE:	20 July 2026
TO:	All Zones - Hematologists, Hematopathologists, Rheumatologists, and Dermatologists
FROM:	Molecular Pathology, Alberta Precision Labs
RE:	**VEXAS Methodology Change**

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message

- As of July 28, 2026, UBA1 gene testing will be available on the myeloid DNA panel performed by the Molecular Pathology, North Sector, lab in Edmonton. All UBA1 testing for VEXAS syndrome will be performed on that panel instead of being sent out to Mayo Medical Laboratories.

Background

- VEXAS is a a severe, progressive autoimmune and blood disorder caused by an acquired mutation in the UBA1 gene. Diagnosis is dependent on detection of UBA1 mutation. Currently, this testing is performed by sendout to Mayo Medical Laboratories. An update to the myeloid DNA panel at the APL Molecular Pathology, North Sector lab in Edmonton has added the UBA1 gene to the available evaluable genes. Therefore, as of July 28, 2026, VEXAS testing will be performed by myeloid DNA panel in Edmonton and send out testing will cease.

How this will impact you

- VEXAS testing will be performed by myeloid DNA panel in Edmonton. Samples collected will be sent to Edmonton for evaluation. The results will be available as Myeloid DNA in EPIC.

Action Required

- None. The VEXAS orderable is still independently available. The collected sample will be automatically routed to Edmonton for myeloid DNA testing. Results will be under the Myeloid DNA test in EPIC.

Effective: July 28, 2026

Questions/Concerns

- Dr. Cheryl Mather, Clinical Lead, Molecular Pathology, North Sector
  Email: cheryl.mather@albertaprecisionlabs.ca

Approved by

- Dr. Cheryl Mather, Medical Lead, Molecular Pathology, North Sector, Alberta Precision Labs
- Dr. Erik Nohr, Molecular Scientific Lead, Molecular Pathology, South Sector, Alberta Precision Labs
- Dr. Carolyn O'Hara, Chief Laboratory Medical Officer, Alberta Precision Labs